The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 12, 2016

Filed:

Jun. 20, 2012
Applicants:

Ralf Hoffmann, Groβpösna, DE;

Nicole Berthold, Leipzig, DE;

Friederike Nollmann, Frankfurt am Main, DE;

Inventors:

Ralf Hoffmann, Groβpösna, DE;

Nicole Berthold, Leipzig, DE;

Friederike Nollmann, Frankfurt am Main, DE;

Assignee:

UNIVERSITAET LEIPZIG, Leipzig, DE;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/16 (2006.01); A61K 38/10 (2006.01); C07K 14/435 (2006.01); C07K 7/08 (2006.01); A61K 47/48 (2006.01); A01N 37/46 (2006.01); A01N 63/02 (2006.01); C12Q 1/37 (2006.01); A01N 25/22 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 47/48215 (2013.01); A01N 25/22 (2013.01); A01N 37/46 (2013.01); A01N 63/02 (2013.01); A61K 38/10 (2013.01); A61K 38/16 (2013.01); C07K 7/08 (2013.01); C07K 14/43563 (2013.01); C12Q 1/37 (2013.01); A61K 38/00 (2013.01);
Abstract

The invention relates to modified antibiotic peptides, in particular derivatives of apidaecin and oncocin, preferably having increased stability, reduced immunoreaction, and improved pharmacokinetics. In the invention, the peptide antibiotics are reversibly protected by means of a linker having the polymer polyethylene glycol (PEG). The peptide linker contains a recognition sequence for trypsin-like serum proteases. In the apidaecin derivatives, the linker and the PEG are bonded to a side chain. In the serum, the linker is cut by serum proteases and PEG is separated off. The released peptide still contains remnants of the linker, which are still bonded to the amino group in the side chain. Astonishingly, said remaining remnants of the linker impair the activity of the antimicrobial peptide only a little or not at all.


Find Patent Forward Citations

Loading…